Ascentage Pharma's Lisaftoclax Shows Promise in Venetoclax-Refractory Patients; ASCO 2025 Presentation
Ascentage Pharma announced positive clinical data for lisaftoclax, a Bcl-2 inhibitor, and alrizomadlin, an MDM2-p53 inhibitor. Data from a Phase 1b/2...